Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02462538 |
|
Recruitment Status :
Terminated
(Due to slow recruitment, recruitment of new patients was stopped, FU was completed for enrolled patients)
First Posted : June 4, 2015
Last Update Posted : March 3, 2022
|
Sponsor:
Arbeitsgemeinschaft medikamentoese Tumortherapie
Information provided by (Responsible Party):
Arbeitsgemeinschaft medikamentoese Tumortherapie
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | November 3, 2021 |
| Actual Study Completion Date : | November 3, 2021 |